Virax Biolabs Group Limited Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Virax Biolabs Group Limited Introduces Avian Influenza A Virus Real-Time PCR Test Kit

VRAX: INITIATION: Innovative Biotechnology Company Developing A Potentially Groundbreaking Immunology Platform Based Around Proprietary T-Cell Testing Technology

by Thomas Kerr, CFA

Virax Biolabs Group Limited Announces Purchase Order to Launch COVID-19 and Influenza A+B Antigen Combo Rapid Tests with Cosmos Health (NASDAQ:COSM)

Virax Biolabs to Present at the 2023 BIO CEO & Investor Conference

Virax Biolabs’ CEO James Foster Issues Letter to Shareholders

Molecular Diagnostics Adapts to Evolving Diseases (feat. Dr. Tomasz George, CSO)

Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances (feat. James Foster, CEO)

Virax Biolabs Introduces Human Papillomavirus (“HPV”) Test Kit

Determining Long Term Immunity May Aid in Understanding Vaccine Efficacy – Interview with Dr. Tomasz George, CSO

by John Parkinson